Misplaced Pages

Rociverine: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 09:11, 28 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,726 edits consistent citation formatting← Previous edit Latest revision as of 01:47, 29 December 2024 edit undoD6dmso (talk | contribs)35 edits →Medical uses 
(3 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{short description|Chemical compound}} {{short description|Chemical compound}}
{{cs1 config|name-list-style=vanc|display-authors=6}} {{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug
{{multiple issues|
| drug_name =
{{context|date=April 2014}}
| INN =
{{one source|date=March 2021}}
| type = <!-- empty -->
}}
| image = Rociverine.svg
{{Drugbox
| width =
| Watchedfields = changed
| alt =
| verifiedrevid = 443791079
| caption =
| IUPAC_name = 2-(diethylamino)-1-methylethyl (1''S'')-1-hydroxy-1,1'-bi(cyclohexyl)-2-carboxylate
| image2 =
| image = Rociverine.png
| width2 =
| alt2 =
| caption2 =
| imageL =
| widthL =
| altL =
| imageR =
| widthR =
| altR =
| captionLR =


<!--Clinical data--> <!-- Clinical data -->
| tradename = | pronounce =
| tradename =
| Drugs.com = {{drugs.com|international|rociverine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | Drugs.com =
| MedlinePlus =
| pregnancy_US = <!-- A / B / C / D / X -->
| licence_CA =
| pregnancy_category =
| licence_EU =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| DailyMedID =
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| licence_US =
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| pregnancy_AU =
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| pregnancy_AU_comment =
| legal_status =
| pregnancy_category=
| routes_of_administration =
| dependency_liability =

| addiction_liability =
<!--Pharmacokinetic data-->
| routes_of_administration =
| bioavailability =
| class =
| protein_bound =
| ATCvet =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number = 53716-44-2
| ATC_prefix = A03 | ATC_prefix = A03
| ATC_suffix = AA06 | ATC_suffix = AA06
| ATC_supplemental =
| PubChem = 68705
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = VI08KS44V0


<!--Chemical data--> <!-- Legal status -->
| C=20 | H=37 | N=1 | O=3 | legal_AU =
| legal_AU_comment =
| synonyms = <small>(1''S'')-1-(diethylamino)propan-2-yl 1-hydroxybi(cyclohexane)-2-carboxylate</small>
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US =
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status =

<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =

<!-- Identifiers -->
| CAS_number = 53716-44-2
| CAS_supplemental =
| PubChem = 24892842
| PubChemSubstance =
| IUPHAR_ligand =
| DrugBank = DB13581
| ChemSpiderID = 28534065
| UNII = VI08KS44V0
| KEGG = D07078
| ChEBI = 135440
| ChEMBL = 4755537
| NIAID_ChemDB =
| PDB_ligand =
| synonyms =

<!-- Chemical and physical data -->
| IUPAC_name = <nowiki>1-(diethylamino)propan-2-yl (1S,2S)-2-cyclohexyl-2-hydroxycyclohexane-1-carboxylate</nowiki>
| C=20 | H=37 | N=1 | O=3
| molecular_weight =
| SMILES = CCN(CC)CC(C)OC(=O)1CCCC1(C2CCCCC2)O
| Jmol =
| StdInChI = InChI=1S/C20H37NO3/c1-4-21(5-2)15-16(3)24-19(22)18-13-9-10-14-20(18,23)17-11-7-6-8-12-17/h16-18,23H,4-15H2,1-3H3/t16?,18-,20+/m1/s1
| StdInChI_comment =
| StdInChIKey = XPYLKZZOBVLVHB-QDKIRNHSSA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}} }}


'''Rociverine''' is an antispasmodic drug used to treat urinary, gastrointestinal and biliary spasms.<ref>{{Cite web |title=Rociverine |url=https://go.drugbank.com/drugs/DB13581}}</ref> It is ] drug.<ref name="pmid582702">{{cite journal | vauthors = Toson G, Schiantarelli P, Murmann W | title = Rociverine, a new antispasmodic agent with balanced neurotropic and myotropic activity | journal = Arzneimittel-Forschung | volume = 28 | issue = 7 | pages = 1130–42 | date = 1978 | pmid = 582702 | doi = | url = }}</ref> '''Rociverine''' is an ] drug used to treat urinary, gastrointestinal and biliary spasms.<ref>{{Cite web |title=Rociverine |url=https://go.drugbank.com/drugs/DB13581}}</ref> It is ] drug.<ref name="pmid582702">{{cite journal | vauthors = Toson G, Schiantarelli P, Murmann W | title = Rociverine, a new antispasmodic agent with balanced neurotropic and myotropic activity | journal = Arzneimittel-Forschung | volume = 28 | issue = 7 | pages = 1130–42 | date = 1978 | pmid = 582702 | doi = | url = }}</ref>

== Medical uses ==

In India, rociverine is used as part of the "Programmed Labour Protocol" to help reduce pain and shorten the duration of labor. However, an analysis of clinical trials provides little evidence supporting its effectiveness in reducing labor duration.<ref name="pmid23737030">{{cite journal | vauthors = Rohwer AC, Khondowe O, Young T | title = Antispasmodics for labour | journal = The Cochrane Database of Systematic Reviews | volume = 2013 | issue = 6 | pages = CD009243 | date = June 2013 | pmid = 23737030 | pmc = 6823273 | doi = 10.1002/14651858.CD009243.pub3 }}</ref>

== Pharmacology ==


The (1R,2R) compound showed 240-fold greater affinity for the muscarinic receptor, but the (1S,2S) compound showed the best selectivity. <ref>{{cite journal | vauthors = Barbier P, Renzetti AR, Turbanti L, Di Bugno C, Fornai F, Vaglini F, Maggio R, Corsini GU | title = Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine | journal = European Journal of Pharmacology | volume = 290 | issue = 2 | pages = 125–132 | date = July 1995 | pmid = 8575526 | doi = 10.1016/0922-4106(95)90024-1 }}</ref> The (1R,2R) stereoisomer showed 240-fold greater affinity for the muscarinic receptor, but the (1S,2S) compound showed the best selectivity. <ref>{{cite journal | vauthors = Barbier P, Renzetti AR, Turbanti L, Di Bugno C, Fornai F, Vaglini F, Maggio R, Corsini GU | title = Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine | journal = European Journal of Pharmacology | volume = 290 | issue = 2 | pages = 125–132 | date = July 1995 | pmid = 8575526 | doi = 10.1016/0922-4106(95)90024-1 }}</ref>


==References== ==References==

Latest revision as of 01:47, 29 December 2024

Chemical compound

Pharmaceutical compound
Rociverine
Clinical data
ATC code
Identifiers
IUPAC name
  • 1-(diethylamino)propan-2-yl (1S,2S)-2-cyclohexyl-2-hydroxycyclohexane-1-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.053.356 Edit this at Wikidata
Chemical and physical data
FormulaC20H37NO3
Molar mass339.520 g·mol
3D model (JSmol)
SMILES
  • CCN(CC)CC(C)OC(=O)1CCCC1(C2CCCCC2)O
InChI
  • InChI=InChI=1S/C20H37NO3/c1-4-21(5-2)15-16(3)24-19(22)18-13-9-10-14-20(18,23)17-11-7-6-8-12-17/h16-18,23H,4-15H2,1-3H3/t16?,18-,20+/m1/s1
  • Key:XPYLKZZOBVLVHB-QDKIRNHSSA-N

Rociverine is an antispasmodic drug used to treat urinary, gastrointestinal and biliary spasms. It is antimuscarinic drug.

Medical uses

In India, rociverine is used as part of the "Programmed Labour Protocol" to help reduce pain and shorten the duration of labor. However, an analysis of clinical trials provides little evidence supporting its effectiveness in reducing labor duration.

Pharmacology

The (1R,2R) stereoisomer showed 240-fold greater affinity for the muscarinic receptor, but the (1S,2S) compound showed the best selectivity.

References

  1. "Rociverine".
  2. Toson G, Schiantarelli P, Murmann W (1978). "Rociverine, a new antispasmodic agent with balanced neurotropic and myotropic activity". Arzneimittel-Forschung. 28 (7): 1130–42. PMID 582702.
  3. Rohwer AC, Khondowe O, Young T (June 2013). "Antispasmodics for labour". The Cochrane Database of Systematic Reviews. 2013 (6): CD009243. doi:10.1002/14651858.CD009243.pub3. PMC 6823273. PMID 23737030.
  4. Barbier P, Renzetti AR, Turbanti L, Di Bugno C, Fornai F, Vaglini F, et al. (July 1995). "Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine". European Journal of Pharmacology. 290 (2): 125–132. doi:10.1016/0922-4106(95)90024-1. PMID 8575526.


Drugs for functional gastrointestinal disorders (A03)
Drugs for
functional
bowel
disorders
Antimuscarinics
Tertiary
amino group
Quaternary
ammonium
compounds
Phosphodiesterase
inhibitors
Acting on
serotonin receptors
Other
Belladonna
and derivatives
(antimuscarinics)
Propulsives
Muscarinic acetylcholine receptor modulators
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Nicotinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: